GT Biopharma, Inc. (GTBP) Key Metrics
GTBP valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $14.5M
- Enterprise value
- $7.9M
- P/E (TTM)
- —
- Forward P/E
- 17.3
- PEG ratio
- 1.05
- Price / sales
- 205.0
- Price / book
- 3.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.85
GTBP key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGTBP returns How much profit the business earns on the capital it uses.
Return on assets−316.1 pts
−459.6%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
GTBP financial health Debt, liquidity and how easily interest is covered.
Net debt−$2.9M
−$6.8M
2025 · hover or tap a bar for each year
20162025
Current ratio+387.5%
3.50
2025 · hover or tap a bar for each year
20162025
Interest coverage
-97.8
2025 · hover or tap a bar for each year
20162025
GTBP valuation history
Fiscal year-endToday10-year median
GTBP returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GTBP debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GTBP cash returned to shareholders
DividendsBuybacksFree cash flow
GTBP price vs earnings per share
Share price at year-endEPS (right axis)
GTBP key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | — | — | — | $846.8M | $2.58B | — | — | — | — | — |
| Enterprise value | — | — | — | $830.4M | $2.54B | — | — | — | — | — |
| Price / book | — | — | — | 72.2 | 117.6 | — | — | — | — | — |
| Earnings yield | — | — | — | −2.5% | −2.3% | — | — | — | — | — |
| Free cash flow yield | — | — | — | −1.8% | −0.6% | — | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — | — | — | — |
| Share price at fiscal year-end | $19.63 | $76.25 | $191.25 | $664.27 | $2,287.50 | $5,406.00 | $1,032.75 | $8,287.50 | $56,737.50 | $356,490.00 |
| Per share | ||||||||||
| Revenue per share | — | — | — | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | — | — | — | −$16.38 | −$51.51 | — | — | — | — | — |
| Operating cash flow per share | — | — | — | −$11.94 | −$13.86 | — | — | — | — | — |
| Free cash flow per share | — | — | — | −$11.94 | −$13.86 | — | — | — | — | — |
| Cash per share | — | — | — | $12.95 | $28.39 | — | — | — | — | — |
| Book value per share | — | — | — | $9.21 | $19.45 | — | — | — | — | — |
| Tangible book value per share | — | — | — | $9.21 | $19.45 | — | — | — | — | — |
| Capex per share | — | — | — | $0.00 | $0.00 | — | — | — | — | — |
| Debt per share | — | — | — | $0.14 | $0.03 | — | — | — | — | — |
| Shares outstanding | — | — | — | 1.3M | 1.1M | — | — | — | — | — |
| Change in shares outstanding | — | — | — | +13.2% | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −79.1% | −124.1% | — | — | — | −196.8% | −123.7% | — |
| Return on invested capital (ROIC) | — | — | — | — | — | — | — | −144.4% | −87.4% | — |
| Return on assets (ROA) | −459.6% | −143.5% | −49.3% | −85.4% | −306.7% | −934.3% | −299.6% | −185.3% | −113.3% | — |
| Return on tangible assets | −349.8% | −311.0% | −53.8% | −124.8% | −180.3% | −499.8% | — | — | — | — |
| Income quality (OCF / net income) | — | — | — | — | — | — | — | — | — | −0.20 |
| Financial health | ||||||||||
| Total debt | — | — | $58,000 | $174,000 | $31,000 | $26.3M | $13.4M | $10.8M | $31,000 | $12.4M |
| Cash & short-term investments | $6.8M | $4.0M | $14.0M | $16.5M | $32.0M | $5.3M | $28,000 | $60,000 | $576,000 | $19,000 |
| Net debt | −$6.8M | −$4.0M | −$13.9M | −$16.3M | −$31.9M | $21.0M | $13.3M | $10.7M | −$545,000 | $12.4M |
| Debt / equity | — | — | 0.01 | 0.01 | 0.00 | — | — | 0.94 | 0.00 | — |
| Debt / assets | — | — | 0.00 | 0.01 | 0.00 | 4.65 | 33.73 | 0.43 | 0.00 | 496.52 |
| Net debt / EBITDA | — | — | −2.33 | — | — | — | — | — | — | — |
| Current ratio | 3.50 | 0.72 | 2.12 | 3.35 | 3.14 | 0.16 | 0.01 | 0.01 | 0.22 | 0.00 |
| Quick ratio | 3.50 | 0.72 | 2.12 | 3.35 | 3.14 | 0.16 | 0.01 | 0.01 | 0.22 | 0.00 |
| Interest coverage | -97.8 | — | -63.7 | — | -80.1 | -2.0 | -5.4 | -27.4 | -15.8 | -1.4 |
| Working capital | $5.8M | −$1.7M | $7.4M | $11.6M | $21.9M | −$29.4M | −$19.4M | −$13.9M | −$2.1M | −$18.9M |
| Invested capital | −$1.0M | −$5.6M | −$6.4M | −$4.6M | −$10.0M | −$8.2M | −$5.8M | $22.3M | $251.3M | −$6.4M |
| Tangible asset value | $5.8M | −$1.7M | $7.5M | $11.7M | $21.9M | −$29.4M | −$19.3M | −$13.9M | −$2.1M | −$18.9M |
| Net current asset value | $5.8M | −$1.7M | $7.4M | $11.6M | $21.9M | −$29.4M | −$19.4M | −$13.9M | −$2.1M | −$18.9M |
| Graham net-net per share | — | — | — | $9.03 | $19.29 | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | $229,000 | $0 | — | — | — | — | — | — | — | — |
| Share buybacks (net) | — | — | $1,000 | $224,000 | $0 | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | — | — | — | 14.8% | — |
| Capex / depreciation | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.14 | 2.00 | 4.00 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | — | 481,940.7% | — |
| R&D / revenue | — | — | — | — | — | — | — | — | 3,955.6% | — |
| SG&A / revenue | — | — | — | — | — | — | — | — | 498,155.6% | — |
| Efficiency | ||||||||||
| Days payables outstanding | — | — | — | — | — | — | 168,903.8 | 112,315.7 | 423,947.5 | 546,222.5 |
| Payables turnover | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $2.3M | $4.1M | $3.7M | $5.7M | $5.2M | $2.1M | $1.9M | $2.2M | $2.3M | $1.5M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 99.5% | 99.8% | 0.0% |
Computed from GTBP's annual financial statements (latest annual report filed March 2, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GTBP valuation and financial ratios
It returned $0.2 million to shareholders: $0.2 million in dividends and $0 in share buybacks.
See the GTBP income statement, the GTBP chart for price history, or the GTBP stock overview for the latest quote and news.
GTBP key metrics FAQ
What is GT Biopharma's current ratio?
GT Biopharma's current ratio was 3.50 at the end of fiscal 2025: current assets were 3.50 times current liabilities.